NxStage Medical (NSDQ:NXTM) won CE Mark approval in Europe for its System 1 technology, which includes new high-flow capabilities to the portable hemodialysis system.
The Lawrence, Mass.-based company is gearing up to distribute this product in the European Union later this year. This win comes on the heels of another CE Mark approval for the nocturnal use of the same System 1 device.
"By providing expanded therapy options, high flow enables NxStage therapy to be even better tailored to the clinical and lifestyle needs of a broader range of patients," said CEO Jeffrey Burbank in a statement.